232.63
price up icon0.72%   1.66
after-market アフターアワーズ: 232.63
loading
前日終値:
$230.97
開ける:
$228.66
24時間の取引高:
865.23K
Relative Volume:
0.79
時価総額:
$25.68B
収益:
$11.28B
当期純損益:
$1.07B
株価収益率:
25.66
EPS:
9.0657
ネットキャッシュフロー:
$1.33B
1週間 パフォーマンス:
+0.18%
1か月 パフォーマンス:
-1.02%
6か月 パフォーマンス:
+21.47%
1年 パフォーマンス:
+26.38%
1日の値動き範囲:
Value
$228.66
$234.64
1週間の範囲:
Value
$226.36
$234.64
52週間の値動き範囲:
Value
$171.18
$248.84

Quest Diagnostics Inc Stock (DGX) Company Profile

Name
名前
Quest Diagnostics Inc
Name
セクター
Healthcare (1051)
Name
電話
(973) 520-2700
Name
住所
500 PLAZA DRIVE, SECAUCUS
Name
職員
57,000
Name
Twitter
@QuestDX
Name
次回の収益日
2026-10-22
Name
最新のSEC提出書
Name
DGX's Discussions on Twitter

Compare DGX vs TMO, DHR, NTRA, A, IQV

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
DGX icon
DGX
Quest Diagnostics Inc
232.63 25.68B 11.28B 1.07B 1.33B 9.0657
TMO icon
TMO
Thermo Fisher Scientific Inc
662.24 244.86B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
221.20 155.50B 24.78B 3.68B 5.29B 5.1743
NTRA icon
NTRA
Natera Inc
397.77 57.34B 2.50B -226.32M 71.51M -1.6412
A icon
A
Agilent Technologies Inc
171.33 48.30B 7.23B 1.41B 1.09B 4.979
IQV icon
IQV
Iqvia Holdings Inc
262.21 43.16B 16.63B 1.39B 2.12B 8.0674

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-30 アップグレード Barclays Equal Weight → Overweight
2025-08-25 ダウングレード Robert W. Baird Outperform → Neutral
2025-04-02 開始されました Redburn Atlantic Buy
2025-03-04 ダウングレード Citigroup Buy → Neutral
2025-01-06 アップグレード Leerink Partners Market Perform → Outperform
2024-12-17 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました Jefferies Buy
2024-10-23 アップグレード Robert W. Baird Neutral → Outperform
2024-08-28 再開されました Evercore ISI In-line
2024-07-10 アップグレード Citigroup Neutral → Buy
2024-02-26 開始されました Leerink Partners Market Perform
2024-02-07 アップグレード Jefferies Hold → Buy
2024-01-03 開始されました Barclays Equal Weight
2023-12-12 アップグレード BofA Securities Neutral → Buy
2023-06-29 開始されました Piper Sandler Neutral
2023-05-02 ダウングレード BofA Securities Buy → Neutral
2023-04-03 アップグレード Citigroup Sell → Neutral
2023-01-23 開始されました Evercore ISI In-line
2022-11-17 ダウングレード Citigroup Neutral → Sell
2022-08-22 再開されました Morgan Stanley Equal-Weight
2022-04-04 ダウングレード Citigroup Buy → Neutral
2022-02-23 ダウングレード UBS Buy → Neutral
2022-02-02 ダウングレード Jefferies Buy → Hold
2022-01-28 ダウングレード Deutsche Bank Buy → Hold
2021-05-04 アップグレード UBS Neutral → Buy
2021-03-12 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-21 アップグレード Argus Hold → Buy
2020-07-29 アップグレード KeyBanc Capital Markets Sector Weight → Overweight
2020-07-14 アップグレード BofA Securities Neutral → Buy
2020-06-09 アップグレード Wells Fargo Underweight → Equal Weight
2020-06-02 アップグレード Deutsche Bank Hold → Buy
2020-04-28 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-04-27 アップグレード Citigroup Neutral → Buy
2020-04-27 アップグレード Wolfe Research Underperform → Peer Perform
2020-03-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-01-08 開始されました Wells Fargo Underweight
2020-01-07 ダウングレード Barclays Overweight → Equal Weight
2019-12-19 アップグレード BofA/Merrill Underperform → Neutral
2019-07-15 ダウングレード Goldman Neutral → Sell
2019-04-02 アップグレード Jefferies Hold → Buy
2019-03-18 再開されました Credit Suisse Neutral
2019-01-31 ダウングレード Argus Buy → Hold
2019-01-17 開始されました UBS Neutral
2019-01-03 ダウングレード BofA/Merrill Neutral → Underperform
2018-12-03 ダウングレード BofA/Merrill Buy → Neutral
2018-11-30 ダウングレード Goldman Buy → Neutral
すべてを表示

Quest Diagnostics Inc (DGX) 最新ニュース

pulisher
Oct 09, 2026

Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investors - ChartMill

Oct 09, 2026
pulisher
Oct 08, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 08, 2026
pulisher
Oct 08, 2026

Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 - www.marketscreener.com

Oct 08, 2026
pulisher
Oct 07, 2026

Quest Diagnostics Incorporated (DGX) options chain - Yahoo Finance UK

Oct 07, 2026
pulisher
Oct 06, 2026

Quest Diagnostics (DGX) Announces Executive Leadership Transitio - GuruFocus

Oct 06, 2026
pulisher
Oct 06, 2026

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 06, 2026
pulisher
Oct 06, 2026

Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 - TradingView

Oct 06, 2026
pulisher
Oct 06, 2026

Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating - marketscreener.com

Oct 06, 2026
pulisher
Oct 06, 2026

Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating - www.marketscreener.com

Oct 06, 2026
pulisher
Oct 06, 2026

Quest Diagnostics Inc's Dividend Analysis - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

Quest Diagnostics (NYSE:DGX) Rides Steady Testing Demand - Kalkine Media

Oct 06, 2026
pulisher
Oct 05, 2026

Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance

Oct 05, 2026
pulisher
Oct 05, 2026

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research

Oct 05, 2026
pulisher
Oct 03, 2026

DGX5874579 Bond Profile: Coupon and Redemption - TradingView

Oct 03, 2026
pulisher
Oct 02, 2026

Three Days Left To Buy Quest Diagnostics Incorporated (NYSE:DGX) Before The Ex-Dividend Date - Moomoo

Oct 02, 2026
pulisher
Oct 02, 2026

Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8 - ChartMill

Oct 02, 2026
pulisher
Oct 01, 2026

Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials - GuruFocus

Oct 01, 2026
pulisher
Sep 29, 2026

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 29, 2026
pulisher
Sep 25, 2026

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - Yahoo Finance

Sep 25, 2026
pulisher
Sep 24, 2026

Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.

Sep 24, 2026
pulisher
Sep 23, 2026

Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - Pluang

Sep 23, 2026
pulisher
Sep 23, 2026

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

Quest Diagnostics Inc (DGX) Stock Down 4.1% but Still Overvalued -- GF Score: 74/100 - GuruFocus

Sep 23, 2026
pulisher
Sep 22, 2026

Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 22, 2026
pulisher
Sep 22, 2026

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Why Quest Diagnostics Holdings Stock Dropped Today - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - Your Wyoming Link

Sep 22, 2026
pulisher
Sep 22, 2026

Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - finance.yahoo.com

Sep 22, 2026
pulisher
Sep 22, 2026

Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - marketscreener.com

Sep 22, 2026
pulisher
Sep 22, 2026

Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Is This the Right Time to Add DGX Stock to Your Portfolio? - TradingView

Sep 22, 2026
pulisher
Sep 22, 2026

Is This the Right Time to Add DGX Stock to Your Portfolio? - Zacks Investment Research

Sep 22, 2026
pulisher
Sep 22, 2026

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Sep 22, 2026
pulisher
Sep 22, 2026

Is Quest Diagnostics Stock Outperforming the Nasdaq? - Barchart.com

Sep 22, 2026
pulisher
Sep 22, 2026

Is Quest Diagnostics Stock Outperforming the Nasdaq? - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Evercore sees Lab Corp, Quest shares facing Medicare pricing headwind By Investing.com - Investing.com Canada

Sep 22, 2026
pulisher
Sep 21, 2026

Labcorp, Quest fall as CMS cuts 2027 rates for laboratory services (LH:NYSE) - Seeking Alpha

Sep 21, 2026
pulisher
Sep 21, 2026

Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView

Sep 21, 2026
pulisher
Sep 21, 2026

Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView

Sep 21, 2026
pulisher
Sep 21, 2026

Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - Yahoo Finance

Sep 21, 2026
pulisher
Sep 21, 2026

Beat the Market Like Zacks: PBF, Palantir, Adobe in Focus - Zacks Investment Research

Sep 21, 2026
pulisher
Sep 21, 2026

Nearly 1 in 3 people with Lyme antibodies had others too. A parasite found alongside Lyme needs different treatment. - Stock Titan

Sep 21, 2026
pulisher
Sep 21, 2026

Truist Raises Price Target on Quest Diagnostics to $260 From $250, Keeps Hold Rating - marketscreener.com

Sep 21, 2026
pulisher
Sep 19, 2026

Quest Diagnostics (DGX) Q1 2026 Earnings Call Transcript - fortune.com

Sep 19, 2026
pulisher
Sep 16, 2026

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance

Sep 16, 2026
pulisher
Sep 16, 2026

96% say lab tests matter as Medicare cuts approach - Stock Titan

Sep 16, 2026
pulisher
Sep 15, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 15, 2026

Quest Diagnostics Inc (DGX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Quest Diagnostics Inc (DGX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Davis J. E.
Officer
Sep 01 '26
Proposed Sale
242.72
10,000
2,427,200
0
PREVOZNIK MICHAEL E
SVP & General Counsel
Aug 28 '26
Sale
243.11
22,677
5,513,083
37,557
PREVOZNIK MICHAEL E
SVP & General Counsel
Aug 28 '26
Option Exercise
112.17
22,677
2,543,679
60,234
PREVOZNIK MICHAEL E
Officer
Aug 28 '26
Proposed Sale
243.11
22,677
5,513,082
0
DELANEY MARK E
Officer
Jul 28 '26
Proposed Sale
235.18
1,600
376,288
0
DELANEY MARK E
SVP & Chief Commercial Officer
Jul 28 '26
Sale
235.18
1,600
376,288
10,335
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
Jun 04 '26
Option Exercise
124.22
8,147
1,012,000
21,657
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
Jun 04 '26
Sale
200.00
8,147
1,629,400
13,510
KUPPUSAMY KARTHIK
Officer
Jun 04 '26
Proposed Sale
200.00
8,147
1,629,400
0
Davis J. E.
CEO and President
Jun 01 '26
Sale
194.14
10,000
1,941,400
132,423
LH LH
$315.52
price up icon 1.08%
GH GH
$162.79
price down icon 2.79%
MTD MTD
$1,563.01
price up icon 0.84%
$155.61
price up icon 0.93%
$620.05
price up icon 1.31%
CRL CRL
$301.86
price up icon 0.02%
大文字化:     |  ボリューム (24 時間):